Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain

Jimenez-Yuste V, Nunez R, Romero JA, Montoro B, Espinos B

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23758100

DOI
10.1111/hae.12199

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Blood Coagulation Factor Inhibitors /blood; Blood Coagulation Factors /therapeutic use; Child; Coagulants /therapeutic use; Cost-Benefit Analysis; Factor VIIa /therapeutic use; Hemophilia A /complications /drug therapy; Hemorrhage /etiology /prevention & control; Humans; Recombinant Proteins /therapeutic use; Severity of Illness Index; Spain

AccessionNumber
22013024300

Date bibliographic record published
24/07/2013